BioCardia will report 2025 financial results and provide a corporate update via conference call on March 24, 2026.
Quiver AI Summary
BioCardia, Inc. has announced that it will hold a conference call on March 24, 2026, at 4:30 PM EDT to discuss its corporate update and financial results for the year ending December 31, 2025. The call will include a formal presentation from management followed by a question-and-answer session. Interested participants can register online to receive dial-in information or can call directly to listen. The conference call will also be accessible via a live webcast, with a replay available shortly after the event until June 24, 2026. BioCardia specializes in developing cell-based therapeutics for cardiovascular and pulmonary diseases, including their CardiAMP® and CardiALLO™ cell therapies. For further information, details are provided in the press release.
Potential Positives
- BioCardia is set to provide a corporate update and report on its financial results, indicating transparency and engagement with stakeholders.
- The conference call will include a question-and-answer session, allowing for real-time interaction and engagement with investors and analysts.
- The availability of both telephonic and webcast options enhances accessibility for a broader audience, potentially increasing investor interest.
- BioCardia’s mention of its biotherapeutic platforms, CardiAMP® and CardiALLO™, highlights its innovative therapeutic approaches in treating significant cardiovascular diseases.
Potential Negatives
- Nothing in the press release indicates specific financial results or significant corporate developments, which may lead to investor uncertainty regarding the company's performance and strategy.
FAQ
When will BioCardia announce its financial results for 2025?
BioCardia will announce its financial results for 2025 on March 24, 2026, at 4:30 PM EDT.
How can I participate in the BioCardia conference call?
Participants can register for the conference call at https://dpregister.com/sreg/10207584/1039b7a7360 to receive dial-in information.
What are the dial-in numbers for the conference call?
U.S. callers can dial 1-833-316-0559, and international callers should use 1-412-317-5730.
Will there be a replay of the conference call available?
Yes, a webcast replay will be available about one hour after the call until June 24, 2026.
What therapies does BioCardia develop for cardiovascular diseases?
BioCardia develops CardiAMP® and CardiALLO™ cell therapies for the treatment of heart disease.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BCDA Insider Trading Activity
$BCDA insiders have traded $BCDA stock on the open market 8 times in the past 6 months. Of those trades, 8 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BCDA stock by insiders over the last 6 months:
- SIMON H STERTZER purchased 398,400 shares for an estimated $498,000
- ANDREW SCOTT BLANK purchased 288,000 shares for an estimated $360,000
- PETER ALTMAN (President and CEO) has made 6 purchases buying 55,000 shares for an estimated $68,288 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BCDA Hedge Fund Activity
We have seen 12 institutional investors add shares of $BCDA stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 94,247 shares (+inf%) to their portfolio in Q4 2025, for an estimated $117,808
- DRW SECURITIES, LLC added 57,607 shares (+inf%) to their portfolio in Q4 2025, for an estimated $72,008
- VANGUARD GROUP INC added 39,063 shares (+40.5%) to their portfolio in Q4 2025, for an estimated $48,828
- GEODE CAPITAL MANAGEMENT, LLC added 27,263 shares (+70.4%) to their portfolio in Q4 2025, for an estimated $34,078
- CETERA INVESTMENT ADVISERS removed 20,275 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $26,154
- TWO SIGMA SECURITIES, LLC removed 19,337 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $24,171
- GSA CAPITAL PARTNERS LLP added 11,303 shares (+inf%) to their portfolio in Q4 2025, for an estimated $14,128
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the year ended December 31, 2025 by conference call on Tuesday, March 24, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.
Participants can register for the conference by navigating to https://dpregister.com/sreg/10207584/1039b7a7360 .
Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=5Vq7aAhd
A webcast replay of the call will be available approximately one hour after the end of the call through approximately June 24, 2026 at the following link: https://services.choruscall.com/ccforms/replay.html . A telephonic replay of the call will also be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada), 1-412-317-0088 (international toll) by using access code 7756290.
About BioCardia®
BioCardia, Inc.
, headquartered in Sunnyvale, California, is a developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. BioCardia also acts as a biotherapeutic delivery partner supporting therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information visit
www.biocardia.com
.
MEDIA CONTACT:
Miranda Peto, Investor Relations
[email protected]
(650) 226-0120
INVESTOR CONTACT:
David McClung, Chief Financial Officer
[email protected]
(650) 226-0120
